Martin Naley founded Cure Forward to solve critical needs in patient care and drug development. Patients had heard of precision medicine but didn’t know how to access tests or targeted therapies. Clinical trials were struggling to find patients. The opportunity became apparent for patients to engage in precision medicine and use their own data to find relevant and specific treatments. Martin incubated the idea at Apple Tree Partners, a healthcare venture capital firm, and the company was formed in 2014. Now the Cure Forward website is launched, helping hundreds of patients who are seeking options in their cancer care. Earlier in his career, Martin spent 15 years at Life Technologies, a manufacturer of the tools that power precision medicine. There, he held various leadership positions including CEO Chief of Staff, Head of Medical Science Informatics, and VP Cell Culture Research. Martin holds a B.A. in Biological Sciences from Cornell and an M.B.A. from Yale.
Martin will show us how a patient can post themselves to the Clinical Trial Exchange, and then receive and accept an invitation to a biomarker-selective clinical trial.